Xenazoic Acid

Summary

Xenazoic Acid (CHEMBL1909289) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 375.4 Da · C23H21NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1909289
Name	Xenazoic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	239062
Molecular formula	C23H21NO4
Molecular weight	375.4
InChIKey	BPOMPTVRBWXZBY-UHFFFAOYSA-N

SMILES: CCOC(C(=O)C1=CC=C(C=C1)C2=CC=CC=C2)NC3=CC=C(C=C3)C(=O)O

IUPAC name: 4-[[1-ethoxy-2-oxo-2-(4-phenylphenyl)ethyl]amino]benzoic acid

Also known as: Acide xenazoique, Acido xenazoico, CV 58903, CV-58903, NSC-43842, NSC-58991, NSC-59182, SKF-8318, Xanalamine, Xenazoic acid, Xenovis, xenazoic acid

Patent coverage: 150 distinct patent families (606 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).